About: Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $57.45 (-3.23%)
ELVNNASDAQEnliven Therapeutics Inc.
Enliven Therapeutics Inc. share price
ELVN price activity
Last Price
$57.450
Change (24hr)
-1.92 USD (-3.23%)
Volume
753.12K
Volume (4w avg)
-
Open
$59.05
Day Range
$57.29 - $59.96
Previous Close
$59.37
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
ELVN price performance
Delayed
09 Sep, 8:00 pm GMT+0
ELVN Market Signals